Loading
A phase 1 trial of FHD-909 run by Eli Lilly and Company, now recruiting.
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors is a phase 1 interventional study registered as NCT06561685 by Eli Lilly and Company, with 340 participants planned, started 2024-09-19. Conditions recorded: Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer and SMARCA4-Deficient Tumor. Interventions recorded: LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel and Nab paclitaxel.
Shares Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/